Mass Spectrometry an Essential Tool for Characterisation of Monoclonal Antibodies During Development

Therapeutic proteins produced in cells using recombinant DNA technology are highly effective and have fewer side effects than small molecule drugs1, 2. Specifically, recombinant monoclonal antibodies (mAb) represent a large portion of therapeutic proteins. The sales of mAbs accounted 51.8% of the $1...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy